Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study…

By B. Giantonio, P. Catalano, N. Meropol, P. O'dwyer, E. Mitchell, S. Alberts, M. Schwartz, A. Benson. Journal of Clinical Oncology, 2007

2,353 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/7d66db10695c406aaeba4f430732c0734bee7217

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Vasudev
2. S. Clarke
3. Fortunato Ciardiello
4. Andrew R Reynolds
5. Rakesh K. Jain

Citations in the corpus

• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) (2010, background): “The clinical benefit of bevacizumab is well established across a range of tumour types, including colorectal cancer [5, 6], metastatic breast [7] and renal cancers [8].”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Metastatic 1st line FOLFIRI ± bevacizumab AVF2107 [19] Improvement in OS and PFS FOLFOX or XELOX ± bevacizumab NO16966 [21] Improvement in OS and PFS Capecitabine ± bevacizumab AVEX [22] Improvement in PFS, OS NA FOLFIRI ± sunitinib SUN1122 [28] No improvement in PFS FOLFOX ± vatalanib CONFIRM 1 [29”
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, neutral): “The TRI‑ COLORE trial, a phase III trial conducted in Japan, compared the efficacy and safety of S‑1 + IRI + BEV with FOLFOX + BEV or CAPOX + BEV as first‑line therapy for PS 0–1 patients with unresectable colorectal cancer.”
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. (2012, background): “vival in the first-line setting when added to irinotecan, bolus fluorouracil and leucovorin(5) or in the second-line setting with the FOLFOX regimen.(6) To”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Disrupting tumour blood supply and angiogenesis has been a enticing target for many years now (158) with some successes in other malignancies such as colorectal cancer (159), ovarian (160) and now cervical cancer (161).”
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Bevacizumab also improves the survival and PFS in combination with FOLFOX in second-line treatment [I, B] [20].”
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “If bevacizumab was not used as the biological first line, it should be considered in second line, as FOLFOX plus bevacizumab was shown to improve OS compared with FOLFOX alone in a phase III trial [282] and confirmed in subsequent studies [283–285].”